TTrialPathMatch Me to Trials
← Back to trials
RecruitingStuttering, AdultStuttering, ChildhoodStuttering, Developmental

Transcranial Alternating Current Stimulation (tACS) in Stuttering

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to investigate how mild, noninvasive electrical brain stimulation affects speech relevant brain areas, which may in turn affect speech fluency and speaking-related brain activity in people that stutter. The long-term goal of this study is to test the therapeutic potential of transcranial alternating current stimulation (tACS) for the treatment of stuttering. The study team hypothesizes that if stuttering involves impaired initiation of motor programs, delta-tuned tACS will strengthen communication between brain regions and decrease stuttering. Therefore, delta-tuned sensorimotor tACS will be paired with fluency-induced speech (choral reading), which is hypothesized to decrease stuttering via improved auditory motor integration.

Sponsor: University of Michigan

You may qualify if…

  • ✓ Have normal language, hearing, and cognition
  • ✓ Speak English as the primary language
  • ✓ Currently stutter
  • ✓ Score (per protocol) a certain value on the Stuttering Severity Instrument (SSI-4).
  • ✓ Have not received any treatment for stuttering within the past year

You may not qualify if…

  • ✕ History of seizures
  • ✕ Major medical or neurological illness (e.g., stroke, serious head trauma, brain infection, Parkinson's disease, etc.)
  • ✕ History of closed head injury with loss of consciousness (e.g., concussion)
  • ✕ Metal or electronic implants such as cochlear implants and pacemakers anywhere in the body
  • ✕ Braids or other hair styling that prevents direct access to the scalp (if removal not possible)
  • ✕ Currently pregnant

Where it's recruiting

Michigan

Ann Arbor

Source: ClinicalTrials.gov · NCT06740968 · last updated 2026-10-13